Otsuka Pharmaceuticals has asked the High Court to overturn a decision revoking its Abilify patent extension, saying the ruling, which limited the extension-of term scheme to active substances only, will “lead to a groundswell of court proceedings”.
Class action settlements hit major milestones last year, with the year’s largest settlements totalling $1.6 billion and one case resolving for a historic $548.5 million.
A judge hearing a class action alleging Bupa failed to provide promised levels of care to residents has said she won’t put the case on ice pending the aged care provider’s potential appeal of a decision declining to toss the case.
German drug maker Merck KGaA is fighting US drug company Merck Sharp & Dohme over the alleged use of the ‘Merck’ mark in Australia, five years after their intellectual property spat was settled.
A medical assessment served under the Wrongs Act by a patient of Dr Daniel Lanzer needed to come to the attention of the surgeon himself, not just his solicitors, despite the lawyers being authorised to receive other documents in the case, an appeals court has found.
A class action against Bupa alleging the aged care provider failed to provide promised levels of care to residents can proceed, with a judge finding the case is not “fatally flawed”.
Mayne Pharma says it, and not US drug maker Cosette, has terminated their $672 merger agreement and that it is therefore not on the hook for a break fee.
A court has slapped private health insurer Bupa with a $35 million penalty after it admitted to misleading thousands of customers about their benefits for over five years.
Setting up another potential legal fight, Mayne Pharma has said US drug maker Cosette did not validly terminate their $672 million merger agreement, which failed to receive FIRB approval.
Johnson & Johnson-owned Janssen has secured an injunction against drug maker Juno Pharmaceuticals, halting the release of Juno’s generic version of schizophrenia drug Invega Sustenna.